Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin

Kohei Kobatake, Keisuke Goto, Yuki Sakamoto, Kyohsuke Iwane, Kensuke Nishida, Kunihiro Hashimoto, Akihiro Asami, Hideo Iwamoto, Tetsutaro Hayashi, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Yohei Sekino, Hiroyuki Kitano, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata

Open source

DOI: 10.1111/iju.15686
Published: 2025-02-10
Container: International Journal of Urology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/iju.15686,
  title = {Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin},
  author = {Kohei Kobatake and Keisuke Goto and Yuki Sakamoto and Kyohsuke Iwane and Kensuke Nishida and Kunihiro Hashimoto and Akihiro Asami and Hideo Iwamoto and Tetsutaro Hayashi and Kenshiro Takemoto and Miki Naito and Shunsuke Miyamoto and Yohei Sekino and Hiroyuki Kitano and Akihiro Goriki and Keisuke Hieda and Nobuyuki Hinata},
  year = {2025},
  journal = {International Journal of Urology},
  doi = {10.1111/iju.15686},
  url = {https://doi.org/10.1111/iju.15686}
}

RIS

TY  - JOUR
TI  - Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin
AU  - Kohei Kobatake
AU  - Keisuke Goto
AU  - Yuki Sakamoto
AU  - Kyohsuke Iwane
AU  - Kensuke Nishida
AU  - Kunihiro Hashimoto
AU  - Akihiro Asami
AU  - Hideo Iwamoto
AU  - Tetsutaro Hayashi
AU  - Kenshiro Takemoto
AU  - Miki Naito
AU  - Shunsuke Miyamoto
AU  - Yohei Sekino
AU  - Hiroyuki Kitano
AU  - Akihiro Goriki
AU  - Keisuke Hieda
AU  - Nobuyuki Hinata
PY  - 2025
JO  - International Journal of Urology
DO  - 10.1111/iju.15686
UR  - https://doi.org/10.1111/iju.15686
ER  -

APA

Kobatake, K., Goto, K., Sakamoto, Y., Iwane, K., Nishida, K., Hashimoto, K., Asami, A., Iwamoto, H., Hayashi, T., Takemoto, K., Naito, M., Miyamoto, S., Sekino, Y., Kitano, H., Goriki, A., Hieda, K., & Hinata, N. (2025). Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin. International Journal of Urology. https://doi.org/10.1111/iju.15686

Source records

crossref · retrieved 2026-09-26T23:56:12.886Z